Assessing the relationship between functional impairment/recovery and depression severity: A pooled analysis

International Clinical Psychopharmacology

Volumn 27, Issue 1, 2012, Pages 1-7

  Guico Pabia, Christine J ^a   Fayyad, Rana S ^a   Soares, Claudio N ^b  

^a PFIZER INC   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

desvenlafaxine; disability; functional outcomes; major depressive disorder

Indexed keywords

DESVENLAFAXINE; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DISABILITY; DISEASE SEVERITY; EMOTION; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; RATING SCALE; REMISSION; SHEEHAN DISABILITY SCALE; WORLD HEALTH ORGANIZATION WELL BEING INDEX;

ADULT; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DISABILITY EVALUATION; EMOTIONS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; RECOVERY OF FUNCTION; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 83055181132     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32834c2488     Document Type: Article

References (43)

1. Adler DA, McLaughlin TJ, Rogers WH, Chang H, Lapitsky L, Lerner D (2006). Job performance deficits due to depression. Am J Psychiatry 163:1569-1576. (Pubitemid 44465757)
2. Bech P (2005). Social functioning: Should it become an endpoint in trials of antidepressants? CNS Drugs 19:313-324. (Pubitemid 40593602)
3. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG (1975). Quantitative rating of depressive states. Acta Psychiatr Scand 51:161-170.
4. Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, et al. (2008). Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 23:243-253.
5. DeMartinis NA, Yeung PP, Entsuah R, Manley AL (2007). A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 68:677-688. (Pubitemid 46841850)
6. Dombrovski AY, Lenze EJ, Dew MA, Mulsant BH, Pollock BG, Houck PR, et al. (2007). Maintenance treatment for old-age depression preserves health-related quality of life: A randomized, controlled trial of paroxetine and interpersonal psychotherapy. J Am Geriatr Soc 55:1325-1332. (Pubitemid 47329232)
7. Feiger AD, Tourian KA, Rosas GR, Padmanabhan SK (2009). A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr 14:41-50.
8. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851-855.
9. Guelfi JD, Ansseau M, Timmerman L, Korsgaard S (2001). Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 21:425-431. (Pubitemid 32673032)
10. Guy W (1976). Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare. pp. 217-222.
11. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
12. Hirschfeld RM, Dunner DL, Keitner G, Klein DN, Koran LM, Kornstein SG, et al. (2002). Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry 51:123-133. (Pubitemid 34127902)
13. Israel JA (2006). Remission in depression: Definition and initial treatment approaches. J Psychopharmacol 20:5-10. (Pubitemid 44605927)
14. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. (2003). The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105. (Pubitemid 37432885)
15. Khan A, Bhat A, Faucett J, Kolts R, Brown WA (2011). Antidepressant- placebo differences in 16 clinical trials over 10 years at a single site: Role of baseline severity. Psychopharmacology (Berl) 214:961-965.
16. Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia C (2010). Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of peri-and postmenopausal women with major depressive disorder. J Clin Psychiatry 71:1088-1091.
17. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV (1997). Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 27:93-105. (Pubitemid 27407503)
18. Lepine JP, Goger J, Blashko C, Probst C, Moles MF, Kosolowski J, et al. (2000). A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression. Int Clin Psychopharmacol 15:263-271. (Pubitemid 30660961)
19. Lieberman DZ, Montgomery SA, Tourian KA, Brisard C, Rosas G, Padmanabhan K, et al. (2008). A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol 23: 188-197.
20. Liebowitz MR, Yeung PP, Entsuah R (2007). A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 68:1663-1672. (Pubitemid 350247495)
21. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA (2008). Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 24:1877-1890.
22. Montgomery S, Ferguson JM, Schwartz GE (2003). The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol 23:45-50. (Pubitemid 36164425)
23. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389. (Pubitemid 9136500)
24. Murray CJ, Lopez AD (1997). Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349: 1498-1504. (Pubitemid 27216360)
25. National Institute for Clinical Excellence (2004). Depression: Management of depression in primary and secondary care.
26. Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ III, et al. (1999). Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 60:221-225. (Pubitemid 29193918)
27. Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA (2007). A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psycho-pharmacol 22:338-347. (Pubitemid 47530838)
28. Sheehan DV (2000). Sheehan disability scale. In: Rush AJ, Pincus HA, First MB, editors. Handbook of psychiatric measures. Washington, DC: American Psychiatric Association. pp. 113-115.
29. Sheehan KH, Sheehan DV (2008b). Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psycho-pharmacol 23:70-83. (Pubitemid 351317279)
30. Sheehan DV, Harnett-Sheehan K, Raj BA (1996). The measurement of disability. Int Clin Psychopharmacol 11 (Suppl 3):89-95. (Pubitemid 26373761)
31. Sheehan DV, Meyers AL, Prakash A, Robinson MJ, Swindle RW, Russell JM, et al. (2008a). The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Curr Med Res Opin 24:2457-2466.
32. Simon GE, Revicki D, Heiligenstein J, Grothaus L, VonKorff M, Katon WJ, et al. (2000). Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 22:153-162. (Pubitemid 30394709)
33. Soares CN, Kornstein SG, Thase ME, Jiang Q, Guico-Pabia CJ (2009). Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: A pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J Clin Psychiatry 70:1365-1371.
34. Solomon DA, Leon AC, Coryell W, Mueller TI, Posternak M, Endicott J, et al. (2008). Predicting recovery from episodes of major depression. J Affect Disord 107:285-291. (Pubitemid 351288934)
35. Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D (2009). Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 31 (Pt 1):1405-1423.
36. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 163:28-40. (Pubitemid 43050100)
37. Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E (2009). Remission, response without remission, and nonresponse in major depressive disorder: Impact on functioning. Int Clin Psychopharmacol 24: 133-138.
38. Von Korff M, Katon W, Rutter C, Ludman E, Simon G, Lin E, et al. (2003). Effect on disability outcomes of a depression relapse prevention program. Psychosom Med 65:938-943. (Pubitemid 38057792)
39. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. (1989). The functioning and well-being of depressed patients: Results from the medical outcomes study. JAMA 262:914-919. (Pubitemid 19208948)
40. Wise TN, Meyers AL, Desaiah D, Mallinckrodt CH, Robinson MJ, Kajdasz DK (2008). The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: A post hoc analysis of 2 trials. Prim Care Companion J Clin Psychiatry 10: 270-275.
41. World Health Organization (1998). Wellbeing Measures in Primary Health Care/The Depcare Project Report on a WHO Meeting, Stockholm, Sweden, 1998. Copenhagen: WHO Regional Office for Europe. i-39.
42. World Health Organization (2001). The World Health Report 2001 Mental Health: New Understanding, New Hope. Geneva: World Health Organiza-tioni. i-178.
43. Zisook S, Peterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I (1998). Treatment of major depression in HIV-seropositive men: HIV Neurobehavioral Research Center Group. J Clin Psychiatry 59:217-224. (Pubitemid 28274604)